Insights of Neuro Oncology

Original Article Pages 56-60

T-DM1 and AVM - Coincidence or Causation: Case Report

Authors: Anika Mittal, MD, Hendrick Tan, FRANZCR, Arlene Chan, FRACP, Constantine Chris Phatouros, FRANZCR, Mihn Lam, FRCPA and Chris Harper, FRANZCR

Abstract: Trastuzumab emtansine (T-DM1) is a novel agent used for the patients with human epidermal growth factor receptor (HER-2) positive breast cancer. Prolonged use of T-DM1 has been shown to cause rare adverse effects, such as hereditary haemorrhagic telangiectasia (HHT)-like symptoms and vascular malformation. The authors present a case of HHT-like symptoms and new brain arteriovenous malformation (AVM) in the setting of T-DM1 therapy for breast cancer.

| | |